|
|
|
Provisional Agenda
Day 1 - Tuesday 20th January 2009
|
|
Session: Cancer Stem Cells |
|
09:30 |
Isolation of Cancer Stem Cells Based on Growth and Survival Properties Shared with Normal Tissue Stem Cells: Cell Surface Antigens Useful As Drug Targets
Jennie Mather, Chief Scientific Officer, Raven Biotechnologies |
|
10:00 |
Cancer Stem Cell Directed Therapy
Stewart Sell, Senior Scientist, Wadsworth Lab NYS Department of Health |
|
10:30 |
Coffee and Networking |
|
Session: Stem Cells in Drug Discovery and Development |
|
11:30 |
Stem Cells as Fundamental Tools for Drug Discovery and Disease-Related Research
Ziwei Huang, Professor, The Burnham Institute for Medical Research |
|
12:00 |
TBC |
|
12:30 |
Poster Session |
|
1:00 |
Lunch and Networking |
|
Session: Regenerative Medicine |
|
2:30 |
Cellular MRI: Tracking The Fate Of Magnetically Labeled Cells Translation From Bench to Bedside
Joseph Frank, Chief Experimental Neuroimaging Section, National Institutes of Biomedical Imaging and Bioengineering and Clinical Center |
|
3:00 |
Use Of Mesenchymal Stem Cells In The Regulation Of Inflammation: Implications For Therapies In The Lung
Mauricio Rojas, Assistant Professor, Emory University |
|
3:30 |
Coffee and Networking |
|
4:00 |
Modeling Myocardial Therapy With Human Embryonic Stem Cells
Harold Bernstein, Professor of Pediatrics (Cardiology), University of California |
|
4:30 |
A First-In-Humans Study Of Safety And Feasibility Of Stem Cell Therapy For AIDS Lymphoma Using Stem Cells Treated With A Lentiviral Vector Encoding Multiple Anti-HIV RNAs
David DiGiusto, Director of Hematopoietic Cell Therapies, City of Hope Medical Center |
|
5:00 |
Reprogramming of Murine Fibroblasts to iPS Cells: Chemical Complementation of Klf4
Costas Lyssiotis, PhD Student, Schultz Lab, The Scripps Research Institute
A small molecule screening platform has been developed to identify compounds that functionally replace retrovirally delivered reprogramming factors. Proof of principal application led to the discovery of a series of chemicals that functionally replace the reprogramming factor Klf4 in the formation of induced pluripotent stem cells. |
|
5:30 |
Drinks Reception / Exhibition Launch |
Day 2 - Wednesday 21st January 2009
|
|
|
|
|
09:00 |
Stem Cells in Research and Regenerative Medicine: The Market Landscape
Enal Razvi, Biotechnology Analyst, Select Biosciences
In this presentation, I will present qualitative and quantitative snapshots of the stem cells market landscape based on our continuous industry coverage. The presentation includes snapshots of the research market along-with penetrance of various technologies for studying stem cells and their market shares. Furthermore, the emphasis is upon regenerative medicine—and R&D as well as clinical trials worldwide are analyzed and the market landscape is presented. Taken together, our continual analysis of this space reveals industry trends and highlights quantitative metrics. |
|
Session: Pluripotency, iPSC |
|
09:30 |
A Study of Enbryonic Stem Cells and Induced Pluripotent Stem Cells in Self Renewal and Differentiation
Jianxin Bao, Research Assistant, Washington University |
|
10:00 |
Putative Ovarian Stem Cells Isolated From Human Adult Ovary And Potential In Vitro OoGensis
Irma Virant-Klun, Director of In Vitro Fertilization Lab, University Medical Centre Ljubljana |
|
10:30 |
Coffee and Networking in Exhibition Hall |
|
11:30 |
Embryomics: High Throughput Generation And Mapping Of Embryonic Progenitors
Michael West, Chief Executive Officer, Embryome Sciences |
|
12:00 |
Non-Neural Stem Cell Based Modeling Of Gliomas
Deepak Kamnasaran, Assistant Professor, Centre de Recherche du CHUL (CHUQ) et Université Laval |
|
12:30 |
Lunch and Networking in Exhibition Hall |
|
Session: Stem Cell Epigenetics |
|
2:30 |
Identification Of Key Pathways And Biomarkers Involved in Human Stem Cell Differentiation By Decoding Promoter Methylation Patterns In Human ES Cells
Jeffrey Falk, Director of Technology applications, Aviva Systems Biology |
|
3:00 |
Key Note Presentation
Forecasting the Impact of President Obama on Stem Cell Policy and Investment
Bernard Siegel, Executive Director, Genetics Policy Institute
The political climate for stem cell research has changed for the better. The inauguration of a new American president will increase funding and bring into focus the regulation of stem cell research, translation and clinical trials. Policy-makers and regulators will be energized to untangle conflicting jurisdictional regulatory schemes.
This presentation offers a blueprint for the next 4 years on how the administration might deliver on the promise of stem cell research. |
|
3:30 |
Coffee and Networking in Exhibition Hall |
|
4:15 |
Adult Mesenchymal Stem Cells Transplant for Fracture Repair
Anna Spagnoli, Associate Professor, University of North Caroline
One of the goals of regenerative medicine is to identify novel cell-based therapies for tissues that lack or fail the repair process. Research in bone marrow derived mesenchymal stem cells (MSC) has had a rapid acceleration over the past decade and MSC-based therapy has become one of the major objects of investigations for regenerative medicine. The fracture repair process fails in twenty percent of the fractures leading to non-unions. Patients with non-unions suffer of long periods of immobilization, pain, bone deformities and even death. Current therapies consist on surgical bone grafts that are associated with complications, inconsistent outcomes and sometime unavailability. MSC transplant represents an attractive therapeutic possibility for patients with non-unions. We have undertaken a comprehensive and integrated approach to define the distinct regenerative contributions of MSC to the fracture repair process. |
|
4:45 |
Key Note Presentation
Human Stem Cells for Repairing Tissue Damage and Treating Orphan Diseases
Jan Nolta, Director - Stem Cell Programme, University of California
Mesenchymal stem cells from the bone marrow and adipose tissue home to hypoxic and/or inflamed areas and secrete bioactive factors that suppress the local immune system, enhance angiogenesis, inhibit fibrosis and apoptosis, and stimulate recruitment, retention, mitosis and differentiation of endogenous tissue-residing stem cells. Gene-modified human MSC, the “paramedics of the body”, are widely distributed throughout all tissues and continue to safely secrete their transgene products at supraphysiological levels for over one year. This strategy provides a platform for the treatment of orphan diseases that result from the absence or mutant function of a key enzyme. |
|
5:15 |
Close of Day 2 |
Day 3 - Thursday 22nd January 2009
|
09:30 |
Cell Cycle Control of Tissue Stem Cells
Tao Cheng, Assiociate Professor, University of Pittsburgh Cancer Institute
Cell cycle regulators as represented by p21 and other CKIs are important modulators for proper functioning of tissue stem cells, thereby serving as potential molecular targets for therapeutic stem cell manipulations. |
|
10:00 |
Epithelial-Mesenchymal Transition and Stem Cells
Sendurai Mani, Professor, University of Texas
We recently found that the induction of epithelial-mesenchymal transition in both normal and transformed human mammary epithelial cells leads to generation of stem-like cells. Similarly, stem cells isolated from breast epithelial cells or carcinoma cells naturally exist in a mesenchymal state. These findings imply that through, we could generate stem-like cells for regenerative medicine and stem cell therapies. Moreover, these findings provide insight into the mechanisms that regulate cancer progression. |
|
10:30 |
Coffee and Networking in Exhibition Hall |
|
11:30 |
Microfluidic Stem Cell Culture System for Real-time Imaging
Cathy Owen, CEO, Nanopoint |
|
12:00 |
Key Note Presentation
A Novel Business Model for Regenerative Medicine
Gail Naughton, Dean San Diego State University
This presentation will discuss the use of novel extracellular matrix and soluble embryonic-like proteins for regenerative medicine in improving medical devices and in the growing arena of bioaesthetics. |
|
12:30 |
Technology Networks Poster Award |
|
12:40 |
Lunch and Networking in the Exhibition Hall |
|
|
Session: Biobanking |
|
14:30 |
The Evolution of a High Capacity, Multi-user Sample Management Network
Michael Hogan, Chief Scientific Officer, GenVault Corporation |
|
15:00 |
Saudi Biobanks - Big Ethical Challenges With Bigger Hopes
Mohammad Al Jumah, Director, King Abdullah International Medical Research Center |
|
15:30 |
Coffee and Networking in Exhibition Hall |
|
16:00 |
The California Birth Defects Monitoring Program, Banking Residual Maternal Blood Samples For Birth Defects Tracking
Gordon Frampton, Repository Manager, California Birth Defects Monitoring Program
The California Birth Defects Monitoring Program maintains one of the largest prenatal blood sample collections in the world. This collection may soon be available to researchers worldwide. Current and future repository plans will be presented. |
|
16:30 |
A Critical Resource; Issues, Challenges & Opportunities
Anil Prasad, Associate Professor of Pathology, University of Arizona Health Sciences Center |
|
17:00 |
Close of Conference | |